IP Library Granted Patent US 11,707,443
Granted Patent B2
US 11,707,443 · App. 17/032,395 · Granted Jul 25, 2023

Storage stable aqueous parenteral solutions comprising diclofenac

Inventors: Kannan Essakimuthu Muthaiyyan (Gujarat, IN); Debjani Manoj Singh (Gujarat, IN); Nirav Ishwarlal Khatri (Gujarat, IN); Sushrut Krishnaji Kulkarni (Maharashtra, IN); Alex Kochukunju George (Gujarat, IN); Sushilkumar Dhanaji Patil (Kolhapur, IN); Jay Shantilal Kothari (Pennington, NJ)
Assignee: RK PHARMA INC.
A61K31/196A61K9/0019A61K47/02A61K47/26A61K47/32A61M5/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,707,443
App. No.
17/032,395
Granted
Jul 25, 2023
Kind
B2
Abstract

The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration.

Claims (16)

1. A parenteral solution comprising diclofenac, polyvinylpyrrolidone, one or more pH adjusting agents, and water, wherein the solution has a pH of between about 7 and about 10.

2. The parenteral solution according to claim 1 , wherein the solution further comprises polysorbate 80 and sodium chloride.

3. The parenteral solution according to claim 1 , wherein the diclofenac is present as diclofenac sodium.

4. The parenteral solution according to claim 3 , wherein the diclofenac sodium is present in a concentration of between about 37.5 mg/mL and about 75 mg/mL.

5. The parenteral solution according to claim 1 , wherein the polyvinylpyrrolidone is present in a concentration of between about 50 mg/mL and about 200 mg/mL.

6. The parenteral solution according to claim 2 , wherein the polysorbate 80 is present in a concentration of between about 5 mg/mL and about 20 mg/mL.

7. The parenteral solution according to claim 1 , wherein the solution has a viscosity of between about 1.5 cP and about 7.5 cP.

8. The parenteral solution according to claim 1 , wherein the solution remains clear after storage for 12 months at controlled room temperature.

9. The parenteral solution according to claim 1 , wherein the solution does not contain impurity A more than 0.5% after storage for 12 months at controlled room temperature.

10. A method for the treatment of pain, the method comprising administering to a human being in need thereof, a solution, via parenteral route, comprising diclofenac, polyvinylpyrrolidone, polysorbate 80, sodium chloride, one or more pH adjusting agents, water, optionally one or more preservatives, optionally one or more antioxidants, and optionally one or more buffering agents, wherein the solution has a pH of between about 7 and about 10.

11. The method according to claim 10 , wherein the solution is provided in a pre-filled syringe.

12. The method according to claim 11 , wherein the pre-filled syringe is assembled/placed in an autoinjector.

13. A method for treatment of migraine, the method comprising administering to a human being in need thereof, a solution, via parenteral route, comprising diclofenac, polyvinylpyrrolidone, polysorbate 80, sodium chloride, one or more pH adjusting agents, water, optionally one or more preservatives, optionally one or more antioxidants, and optionally one or more buffering agents, wherein the solution has a pH of between about 7 and about 10.

14. The method according to claim 13 , wherein the method is for the acute treatment of migraine attacks.

15. The method according to claim 13 , wherein the parenteral route is a subcutaneous route.

16. The method according to claim 13 , wherein the method comprises administering the solution of diclofenac via subcutaneous route, and wherein the diclofenac is present from about 12.5 mg to about 100 mg.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2026
From: RK PHARMA INC.
To: ADVENTA PHARMA DWC LLC
Reel/Frame 075909/0846 →
SECURITY INTEREST Recorded May 8, 2024
From: RK PHARMA INC.
To: CITIBANK, N.A.
Reel/Frame 067343/0089 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 063662 FRAME: 0287. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 23, 2023
From: ZYDUS LIFESCIENCES LIMITED
To: RK PHARMA INC.
Reel/Frame 064082/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2023
From: ZYDUS LIFESCIENCES LIMITED
To: R.K. PHARMA INC.
Reel/Frame 063662/0287 →
CHANGE OF NAME Recorded Feb 21, 2023
From: CADILA HEALTHCARE LIMITED
To: ZYDUS LIFESCIENCES LIMITED
Reel/Frame 062748/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2022
From: MUTHAIYYAN, KANNAN ESSAKIMUTHU; SINGH, DEBJANI MANOJ; KHATRI, NIRAV ISHWARLAL; KULKARNI, SUSHRUT KRISHNAJI; GEORGE, ALEX KOCHUKUNJU; PATIL, SUSHILKUMAR DHANAJI; KOTHARI, JAY SHANTILAL
To: CADILA HEALTHCARE LIMITED
Reel/Frame 061466/0860 →
Priority Claims (1)
IN 201921038953 · Sep 26, 2019 · national
Continuity (1)
Related Publication 20210093598A1 · Apr 1, 2021